

Towards Performing Internal Quality-Control (IQC) Parameters in Clinical Laboratory

Mohammad Najafi*

Biochemistry Department, Cellular and Molecular Research Center, Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran

Abstract

The clinical and analytical specificity and sensitivity are dependent on the advancement of laboratory tools. Hereupon, one of the main aims of new laboratory equipments is to develop the Limitations of Detection (LOD) of trace markers. Although the routine use of low LOD markers may be critical in clinical diagnoses but, the quality-control parameters should be managed during their measurements. It is obvious that the data assurances are associated to tools, methods and materials, but a simple concept must be followed for data quality analysis in clinical laboratories. Here, some IQC parameters are mentioned to be applied and evaluated by staffs in clinical laboratories.

Standard Curve

The standard curves may be prepared on the basis of line or scatter modes (Figure 1). The line mode is suggested when the standard points are not correlated or the changes of the different standard concentrations are not fitted on the regression curve. In this mode, near standard points may be independently associated on the line. In scatter mode, the distances of standard points from the fitted line are at the allowable range so that the best standard equation is plotted on the boot-strapping technique and the Root-Mean-Square Error (RMSE).

Quality-Control Parameters

With the consideration of significant benefits of quality management in improvement of industry products [1], the quality-control definitions and terms were used in the clinical laboratory fields [2]. However, the approaches of managing were different in two fields based on the material characteristics and sample repeatability. While the primary materials in the industry products are almost the same but, the laboratory sample matrices are different on individual variations [3]. Moreover, the use of pooled sample and calibrator instead of the patient sample is due to the limitations on the laboratory repeatability [4].

The quality-control parameters are most important factors to




Figure 1: Standard curves with Line and scatter modes. In the above plot, the standard points 6-10 are placed between 15000 and 16300 and between 13200 and 17100 in the line and scatter modes, respectively. The bottom plot shows the predicted errors for standard points on the logarithmic equation ($y=151.78+7380.76*\ln(x)$, best RMSE).

consider the uncertainty. Several essential questions must be answered before studying this factor. What is the definition of ARL (Average Run Length)? How many calibrators (or pooled samples) should be used in each run ($1/P_{fr}$)? How to merge the random and systematic errors? What are the differences of intra-run and inter-run parameters? How to interpret data in each run? My idea is to simplify the IQC measurement conditions by to be concentrated on the basic concepts and reducing of problematic and amazing rules and instructions.

Intra-run quality parameters

In this state, allowable total error (TE_a) containing random (Imprecision) and systematic (Inaccuracy) errors (RE and SE) may be used for the decision on the run rejection or acceptance (analytical quality assurance) when their position are identified on OPS_{PECS} Chart [5]. Without consideration of the number of samples in each run, I suggest the use of three calibrators (or pooled samples) to calculate the allowable total error (TE_a). The TE_a Chart for each laboratory marker can be prepared in the following way:

RUN	Mean \pm SD	Value _{Exp} -Mean _{Obs}
Run1	Mean _{Obs1} \pm SD ₁	Value _{Exp} -Mean _{Obs1}
.	.	.
.	.	.
.	.	.
Run6	Mean _{Obs6} \pm SD ₆	Value _{Exp} -Mean _{Obs6}
Total	Mean _{MeanObs} \pm SD	MeanValue _{Exp} -Mean _{Obs}

Three calibrators (cal1+cal2+cal3) are evaluated in each run; Total distribution means should be harmonized; Exp, Expected calibrator value; Obs, Observed calibrator value.

*Corresponding author: Mohammad Najafi, Biochemistry Department, Cellular and Molecular Research Center, Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran, Tel: 982188622742; Fax: 982188622742; E-mail: nbsmmsbn@tums.ac.ir

Received March 21, 2013; Accepted April 05, 2013; Published April 08, 2013

Citation: Najafi M (2013) Towards Performing Internal Quality-Control (IQC) Parameters in Clinical Laboratory. Adv Tech Biol Med 1: 105. doi:10.4172/2379-1764.1000105

Copyright: © 2013 Najafi M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

$$TE_{\alpha} = B_{ias} + \Delta SE + \Delta RE + ZSD$$

$$\Delta SE \text{ and } \Delta RE \square 0,$$

$$B_{ias} = \left(\frac{\text{Mean Value Exp} - \text{Mean Obs}}{\text{Value Exp}} \right) \times 100$$

$$RE_{\alpha} = \left(\frac{SD}{\text{Mean Mean Obs}} \right) \times 100$$

$$\text{If } TE_{\alpha} = 100$$

Thus,

$$100 = \text{Bias}(\% \text{ of } TE_{\alpha}) + ZSD(\% \text{ of } TE_{\alpha})$$


$$B_{ias}(\% \text{ of } TE_{\alpha}) = 100 - ZSD(\% \text{ of } TE_{\alpha})$$

$$\text{If } B_{ias}(\% \text{ of } TE_{\alpha}) = 0$$

$$\text{for } Z = 1.98 (p = 0.975) \quad SD(\% \text{ of } TE_{\alpha}) = \frac{100}{1.98} = 50.5$$

$$\text{And for } Z = 1.64 (p = 0.95) \quad SD(\% \text{ of } TE_{\alpha}) = \frac{100}{1.64} = 60.97$$

$$SD(\% \text{ of } TE_{\alpha}) = 0 \quad B_{ias}(\% \text{ of } TE_{\alpha}) = 100$$



With the use of desirable TE_{α} [6] and the calculation of $B_{ias}(\% \text{ of } TE_{\alpha})$ and $SD(\% \text{ of } TE_{\alpha})$ parameters in each run, and also its identification in the TE_{α} chart, we can make a decision on the run rejection or acceptance. The numbers of total errors in each run are dependent on the linearity and degree of standard curve.

Inter-run quality parameters

One of the main aims to evaluate the between-run variations is to determine the quality of the methods and materials. Levey-Jennings control chart is widely used and developed on Westgard rules [7]. Several factors such as the calibrator (or pooled sample)/sample ratio, the multiple rules must be considered on using the chart.

I suggest the calibrator re-distribution in loop mode (Figure 2) since in the Levey-Jennings control chart, each the calibrator is independently evaluated without the consideration of its role in the data distribution. Although the suggested approach does not show the trends but it omits the primary bias on preparation of rough plot, the redundancy rules




Figure 2: Re-distribution in a loop mode. With adding a calibrator (n+1), all calibrators should be re-distributed so that the distribution more than 5% in each subsection can be important on the quality of methods and materials and also run data (Z=2).

and the prediction of the number of calibrators in each run. In this mode, we need only to check the calibrator distributions based on the Z score.

In conclusion, there are two important parameters to evaluate the quality of run data and measuring methods, the TE_{α} and re-distribution charts. The decision on run rejection method can be obtained using the TE_{α} chart and, the method accuracy may be evaluated with the calibrator re-distribution in loop mode.

References

1. Shewhart Walter A (1939) Statistical method from the viewpoint of quality control. Dover Publications Washington, D.C.
2. LEVEY S, JENNINGS ER (1950) The use of control charts in the clinical laboratory. Am J Clin Pathol 20: 1059-1066.
3. Fraser Callum G (2001) Biological variation: from principles to practice. AACC Press, Washington, DC.
4. Henry RJ, Segalove M (1952) The running of standards in clinical chemistry and the use of the control chart. J Clin Pathol 5: 305-311.
5. Westgard JO (1992) Charts of operational process specifications ("OPSpecs charts") for assessing the precision, accuracy, and quality control needed to satisfy proficiency testing performance criteria. Clin Chem 38: 1226-1233.
6. Ricós C, Alvarez V, Cava F, García-Lario JV, Hernández A, et al. (1999) Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest 59: 491-500.
7. Carroll TA, Pinnick HA, Carroll WE (2003) Probability and the Westgard Rules. Ann Clin Lab Sci 33: 113-114.